These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21594976)

  • 21. Assessing the quality of healthcare provided to children.
    Mangione-Smith R; McGlynn EA
    Health Serv Res; 1998 Oct; 33(4 Pt 2):1059-90. PubMed ID: 9776949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving toxicity screening and drug development by using genetically defined strains.
    Festing MF
    Methods Mol Biol; 2010; 602():1-21. PubMed ID: 20012389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development.
    Barrow PC; Schmitt G
    Methods Mol Biol; 2017; 1641():25-67. PubMed ID: 28748457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of juvenile animal testing for small and large molecules.
    Baldrick P
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):125-35. PubMed ID: 23896345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usage of unpublished paediatric data.
    Saint-Raymond A; Pelle B; Zaccaria C; Sennwitz M; Branch S
    Arch Dis Child; 2016 Jan; 101(1):81-4. PubMed ID: 26543071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Points to Consider in Designing and Conducting Juvenile Toxicology Studies.
    Kim NN; Parker RM; Weinbauer GF; Remick AK; Steinbach T
    Int J Toxicol; 2017; 36(4):325-339. PubMed ID: 28466670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging trends in contract research industry in India.
    Drabu S; Gupta A; Bhadauria A
    Contemp Clin Trials; 2010 Sep; 31(5):419-22. PubMed ID: 20609394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Juvenile Toxicology: Relevance and Challenges for Toxicologists and Pathologists.
    Remick AK; Catlin NR; Quist EM; Steinbach TJ; Dixon D
    Toxicol Pathol; 2015 Dec; 43(8):1166-71. PubMed ID: 26220944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials in pediatrics: The drug delivery dimension.
    Osuntokun B
    Adv Drug Deliv Rev; 2006 Apr; 58(1):90-105. PubMed ID: 16529842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complexity of the body calls for animal research.
    Smith CG
    Nature; 2004 Sep; 431(7005):125. PubMed ID: 15356604
    [No Abstract]   [Full Text] [Related]  

  • 36. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
    Parkinson C; Thomas KE; Lumley CE
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical studies in pediatrics: challenges and actual developments].
    Ohmann C
    Klin Padiatr; 2008; 220(4):221-3. PubMed ID: 18654944
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric clinical trial experience: government, child, parent and physician's perspective.
    Salazar JC
    Pediatr Infect Dis J; 2003 Dec; 22(12):1124-7. PubMed ID: 14688585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.